Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097-6110.
Alvarado-Miranda A, Lara-Medina FU, Muñoz-Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, Sanchez Benitez D, Limón Rodríguez JA, Arce Salinas CH, Guijosa A, Arrieta O. Alvarado-Miranda A, et al. Among authors: lara medina fu. Curr Oncol. 2024 Nov 15;31(11):7177-7179. doi: 10.3390/curroncol31110529. Curr Oncol. 2024. PMID: 39590178 Free PMC article.
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Alvarado-Miranda A, Lara-Medina FU, Muñoz-Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, Sanchez Benitez D, Limón Rodríguez JA, Arce Salinas CH, Guijosa A, Arrieta O. Alvarado-Miranda A, et al. Among authors: lara medina fu. Curr Oncol. 2023 Jun 24;30(7):6097-6110. doi: 10.3390/curroncol30070454. Curr Oncol. 2023. PMID: 37504314 Free PMC article.
68Ga-DTPA Anti-HER2 positron emission tomography/CT successfully predicts the overexpression of human epidermal growth factor receptor in lung metastases from breast cancer.
Pitalúa-Cortés QG, García-Pérez FO, Villaseñor-Navarro Y, Lara-Medina FU, Matus-Santos JA, Soldevilla-Gallardo I, Porras-Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Pérez-Báez W, Sollozo-Dupont I. Pitalúa-Cortés QG, et al. Among authors: lara medina fu. BJR Case Rep. 2017 May 6;3(3):20160136. doi: 10.1259/bjrcr.20160136. eCollection 2017. BJR Case Rep. 2017. PMID: 30363270 Free PMC article.
[Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
Arce-Salinas C, Lara-Medina FU, Alvarado-Miranda A, Castañeda-Soto N, Bargalló-Rocha E, Ramírez-Ugalde MT, Pérez-Sánchez V, Rivera L, Gambo-Vignole C, Santamaría-Galicia J, Nieves-Casas RI, Morán-Muñoz H, Mohar-Betancourt A. Arce-Salinas C, et al. Among authors: lara medina fu. Rev Invest Clin. 2012 Jan-Feb;64(1):9-16. Rev Invest Clin. 2012. PMID: 22690524 Spanish.